We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The approval of the twice-daily doses was based on a reduction in serum ferritin levels, as there were no controlled trials demonstrating a direct treatment benefit. Read More
The company is involving local Japanese medical institutions in its project, beginning with Yokohama’s Kanagawa Cardiovascular and Respiratory Center. Read More
The system has been shown to improve the immune response to vaccines and is easy to administer in wide-scale immunization settings, said PharmaJet’s CEO Chris Cappello. Read More